Milestone Pharmaceuticals Inc (MIST)

Etorro trading 970x250
Milestone Pharmaceuticals Inc (MIST) Logo

About Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada. Address: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6

Milestone Pharmaceuticals Inc News and around…

Latest news about Milestone Pharmaceuticals Inc (MIST) common stock and company :

70 Biggest Movers From Yesterday
16 Nov, 2021 FinancialContent

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be ...

Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
15 Nov, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data from a post-hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The analysis demonstrated that etripamil sig

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov, 2021 FinancialContent

Biotech stocks declined for the second straight week amid a broader market pullback, along withearnings news from small- and ...

Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
12 Nov, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update.

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
11 Nov, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 18% over the last year
15 Oct, 2021 Yahoo! Finance

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
22 Sep, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.

Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.

What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)?
16 Aug, 2021 Yahoo! Finance

If you want to know who really controls Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ), then you'll have to look at the...

Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
11 Aug, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update.

10 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital
03 Aug, 2021 Yahoo! Finance

In this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani’s Ikarian Capital. To skip our detailed analysis of Shahrestani’s history, hedge fund performance, and investment philosophy, go directly to the 5 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital. Neil Shahrestani, MD, is the Chief Investment Officer, managing […]

12 Health Care Stocks Moving In Tuesday's After-Market Session
06 Jul, 2021 FinancialContent

Gainers Opiant Pharmaceuticals (NASDAQ:OPNT) stock increased by 35.04% to $17.9 during Tuesday's after-market session. Opiant ...

Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
26 May, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET. The conference will be held in a virtual meeting format.

Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
22 May, 2021 FinancialContent

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.

Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
17 May, 2021 FinancialContent

Milestone Pharmaceuticals Inc(NASDAQ: MIST)hit a major snag last Marchwhen its investigational etripamil nasal ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
17 May, 2021 FinancialContent

Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) shares increased by 20.68% to $1.4 during Monday's pre-market session. ...

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
17 May, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of data related to key secondary endpoints from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The oral presentation, titled "Etripamil Nasal Spray Relieves Symptoms And Reduces Emergency Room Interventions In Patients With Paroxysmal Supraventricular Tachycardia (PSVT): Analysis Of Clinical Outcomes In The Node-301 Trial", was featured during a late-breaker session at the American College of Cardiology's 70th Annual Scientific Session (ACC.21) that was held in a virtual format. A copy of the presentation will be available in the Publications section of Milestone's website.

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
17 May, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
17 May, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China. Ji Xing is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW) focused on advancing innovative medicines in China.

Ji Xing Acquires Tachycardia Treatment in $127.5 Million Deal
17 May, 2021 FinancialContent

Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma (NSDQ: MIST) in a $127.5 million agreement. Ji Xing's backer, RTW Investments, a New York company focused on innovative medicines for China, will make a $15 million upfront payment to Milestone and invest $5 million in the company. Ji Xing will be responsible for up to $107.5 million in milestone payments. Milestone is conducting a US Phase III trial of the candidate, etripamil, a nasal treatment for paroxysmal supraventricular tachycardia. More details.... Share this with colleagues:

Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
04 May, 2021 Yahoo! Finance

Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
03 May, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Milestone Pharmaceuticals Stock Is a Bet On Etripamil
02 Apr, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update
29 Mar, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update.

Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
29 Mar, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate (AFib-RVR), or the ReVeRA study.

Relative Strength Alert For Milestone Pharmaceuticals
26 Mar, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Should Investors Consider Buying These Top Health In March? 4 To Watch
05 Mar, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021
05 Mar, 2021 FinancialContent

Upgrades For Boeing Co (NYSE:BA), Canaccord Genuity upgraded the previous rating of Hold to Buy. In the fourth quarter, ...

10 Health Care Stocks Showing Unusual Options Activity In Today's Session
03 Mar, 2021 FinancialContent

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the ...

The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
13 Nov, 2020 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Milestone Pharmaceuticals Inc (MIST) is a NASDAQ Common Stock listed in , ,

970x250